Dongde Wu
Tongji Medical College
7 Papers
Dongde Wu is an academic researcher from Tongji Medical College. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
6PGD inhibition sensitizes hepatocellular carcinoma to chemotherapy via AMPK activation and metabolic reprogramming.
TL;DR: This work shows that 6-phosphogluconate dehydrogenase (6PGD), a key enzyme of the oxidative pentose phosphate pathway, is important for HCC growth and survival and suggests 6PGD as a promising therapeutic target to overcome chemoresistance in HCC.
47
Decreased propionyl-CoA metabolism facilitates metabolic reprogramming and promotes hepatocellular carcinoma.
Jiaqi Sun,Jun Ding,Qingsong Shen,Xiyang Wang,Min Wang,Yongping Huang,Xuechun Zhang,Hua Zhu,Feng zhang,Dongde Wu,Min-Wen Peng,Zhonglin Zhang,Yufeng Yuan,Wenhua Li,Zhi-Gang She,Xiao‑Jing Zhang,Hongliang Li,Peng Zhang,Zan Huang +18 more
TL;DR: In this article , the role of propionyl-CoA metabolism in hepatocellular carcinoma (HCC) was dissected and the potential targets for development of novel strategies against HCC were uncovered.
26
Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Preliminary results from a pooled analysis of two phase I studies.
Ying Yuan,Yanhong Deng,Yueyin Pan,Cunji Wang,Zhiwu Wang,Zhiye Zhang,Xiangjiao Meng,Yi Hu,Huijuan Wang,Nong Yang,Dongde Wu,Xiaorong Dong,Dingzhi Huang,Meili Sun,Liang Liu,Dong Hua,Zengqing Guo,Kefeng Ding +17 more
TL;DR: IBI351 (GFH925) is an irreversibly covalent inhibitor of KRASG12C and has demonstrated promising anti-tumor activity with acceptable safety in advanced solid tumors as mentioned in this paper .
3
miR-575/RIPK4 axis modulates cell cycle progression and proliferation by inactivating the Wnt/β-catenin signaling pathway through inhibiting RUNX1 in colon cancer.
Qun Wang,Weijun Lu,Li Lu,Ruopu Wu,Dongde Wu +4 more
1
ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after surgical resection.
Xianhai Mao,Xiaohui Duan,Dongde Wu,Cuncai Zhou,Yifeng Tian,Jinfang Zheng,Changbo Fu,Guohui Xu,Yannan Bai,Changxiong Wu +9 more
TL;DR: Anlotinib plus TQB2450, an anti-PD-L1 mAb, has shown promising anti-tumor activity and manageable toxicity as first or second-line treatment for patients with advanced HCC in an open-label phase II trial as discussed by the authors .